BERYL DRUGS LIMITED
Regd. Off.: Ground Floor, 133, Kanchan Bagh, **Indore** - 452001 (M.P.)
Tel. : (0731) 2517677 | **E-mail :** beryldrugs25@yahoo.com | **CIN :** L02423MP1993PLC007840

Date: 09th February, 2026

To,

The Secretary,
Department of Corporate Services,
Bombay Stock Exchange Limited (BSE),
Phiroze JeeJeebhoy Towers, Dalal Street,
Mumbai – 400001

Scrip Code: 524606

Sub.: Disclosure of Regulation 30 read with Part- A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the quarter ended 31st December, 2025

Dear Sirs,

Pursuant to Regulation 30 read with Part- A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that the Board of Directors in its Board Meeting held on 9th February, 2026 has approved the Unaudited Financial Results of the Company for the Quarter ended 31st December, 2025 and Limited Review Report by the Auditors for the unaudited Financial Results of the Company for the Quarter ended on 31st December, 2025.

We hereby request you to kindly acknowledge the receipts of same.

Thanking You,

Yours Sincerely

For Beryl Drugs Limited

Sudhir Sethi
Chairman& Director
DIN: 00090172

BERYL DRUGS LIMITED
133, Kanchan Bagh, Indore (M.P.) – 452001
Tel./ Fax 0731-2517677
E-mail : beryldrugs25@yahoo.com

ANNEXURE I

Submission of Unaudited Financial Result by Companies Other than Banks

Part I

(Rs in lacs)

Statement of standalone Unaudited Result for the Quarter ended 31/12/2025

Particulars	Quarter ended			Half year ended		Year ended
	3 months ended (31-12-2025)	Preceding 3 months ended (30-09-2025)	Corresponding 3 months ended in the previous year (31-12-2024)	Year to date figures for current period ended (31-12-2025)	Year to date figures for previous period ended (31-12-2024)	Previous year ended (31-03-2025)
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1 Income						
(a) Revenue From Operations						
Net sales or Revenue from Operations	377.68	512.00	530.93	1369.11	1717.26	2114.62
Other operating revenues	7.36	3.66	9.34	15.17	16.26	140.85
Total Income	**385.04**	**515.66**	**540.27**	**1384.28**	**1733.52**	**2255.48**
2 Expenses						
(a) Cost of materials consumed	208.19	278.90	262.77	707.96	865.66	1112.14
(b) Purchases of stock-in-trade	0.00	0.00	0.00	0.00	0.00	0.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-4.53	-20.76	-79.41	-43.63	-68.95	-33.70
(d) Employee benefit expense	78.91	57.68	62.01	189.98	161.78	221.22
(e) Finance costs	9.17	8.02	12.04	27.28	45.07	52.97
(f) Depreciation and amortisation expense	31.83	39.15	31.26	109.06	92.91	124.56
(g) Other Expenses	122.25	126.64	235.55	421.41	560.66	691.72
Total expenses	**445.82**	**489.63**	**524.22**	**1412.06**	**1657.13**	**2168.92**
3 Profit before tax (1-2)	**-60.78**	**26.03**	**16.05**	**-27.78**	**76.39**	**86.56**
4 Tax Expense						
Current tax	-18.40	10.66	8.51	7.26	34.69	20.11
Mat Credit Entitlement	0.00	0.00	0.00	0.00	0.00	0.00
Adjustments in respect of current income tax of prior years	0.01	0.68	-1.08	0.69	-1.08	-1.09
Deferred tax	-25.62	13.80	3.40	-21.96	0.08	9.66
Total Tax Expenses	**-44.01**	**25.14**	**10.83**	**-14.01**	**33.69**	**28.68**
5 Profit after tax (3- 4)	**-16.77**	**0.89**	**5.22**	**-13.77**	**42.70**	**57.88**
Other comprehensive income	6.83	-6.77	0.26	0.30	0.78	0.16
6 Total Comprehensive Income	**-9.94**	**-5.88**	**5.48**	**-13.47**	**43.48**	**58.05**
7 Details of equity share capital						
Paid-up equity share capital	507.17	507.17	507.17	507.17	507.17	507.17
Face value of equity share capital	10.00	10.00	10.00	10.00	10.00	10.00
8 Earnings per share						
(a) Basic earnings per share before extraordinary items	-0.33	0.02	0.10	-0.27	0.84	1.14
(b) Diluted earnings per share before extraordinary items	-0.33	0.02	0.10	-0.27	0.84	1.14

Notes:

1. The above financial results have been prepared in accordance with the recognition and measurement principles stated therein prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.
2. The above results for the quarter ended 31st December 2025 which have been subjected to Limited Review by Statutory Auditors of the Company were reviewed and recommended by the Audit Committee and subsequently by the Board of Directors at its meeting held on 14th Nov.2022 in terms of regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) , Regulation, 2015.
3. The Income from Operations is from one segment namely "Pharmaceutical Industry".
4. The figures for the previous periods have been regrouped, wherever necessary.
5. Depreciation is provided on Written down value method on the estimated remaining useful lives of the assets.
6. The Company has considered internal and external information upto the date of approval of these financial results in assessing the recoverability of financial and non financial assets, based on which it expects to recover the carrying amount of these assets. The eventual outcome of impact of global health pandemic may be different from those estimated as on the date of approval of these financial results.
7. A part of the Company's manufacturing facility was under suspension w.e.f 11/02/2025 and upgradation pursuant to directions issued by the State Food and Drugs Administration (FDA). The Company submitted a point-wise rectification and compliance report along with supporting documents and photographs in response to the said directions. Subsequently, the State Food and Drugs Administration, vide its order, has permitted continuation of operations of the concerned section with effect from 28 November 2025. Accordingly, the suspension on the said part of the manufacturing facility stands lifted from that date.
8. Earnings per Share amount is Shown in Rupees.
9. The above results were taken on record at the meeting of the board of director held of February 09 th, 2026.

BERYL DRUGS LTD. Director

For and on behalf of the Board of Directors
For Beryl Drugs Limited

Sanjay Sethi
Managing Director
DIN : 00090277

Date: 09/02/2026
Place:Indore

Subhash Chand Jain Anurag & Associates

Chartered Accountants

104, Archana Apartment, 8-B, Ratlam Kothi, Indore-452001 (MP)
PH # 2519439, 2527682 FAX # 0731 2519116
Mobile No.: +91-93021-23882
Email: scjainca2004@yahoo.com

Independent Auditor's Review Report on Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

The Board of Directors
Beryl Drugs Limited
Gr. Floor 133, Kanchan Bagh
Indore (M.P.)

1. We have reviewed the accompanying statement of unaudited financial results of **Beryl Drugs Limited** ("the Company") for the quarter ended December 31, 2025 and year to date results for the period from April, 01 2025 to December 31, 2025 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 and Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended (the "Listing Regulations'}.

2. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors and prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34) prescribed under section 133 of the Companies Act, 2013 read with rule 3 of Companies (Indian Accounting Standard) rules 2015, as amended read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410,"Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consist of making inquiries, primarily of persons responsible for financial and accounting matters,

SUBHASH CHAND JAIN & ANURAG & ASSOCIATES • Chartered Accountants • FRN. 004733C INDORE

and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33, Regulation 52 and Regulation 54 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

5. Attention is drawn to Notes to the statement:

   a) **Note No. 7:** A part of the Company's manufacturing facility was under suspension w.e.f 11/02/2025 and upgradation pursuant to directions issued by the State Food and Drugs Administration (FDA). The Company submitted a point-wise rectification and compliance report along with supporting documents and photographs in response to the said directions. Subsequently, the State Food and Drugs Administration, vide its order, has permitted continuation of operations of the concerned section with effect from 28 November 2025. Accordingly, the suspension on the said part of the manufacturing facility stands lifted from that date.

For Subhash Chand Jain Anurag & Associates
Chartered Accounts
FRN: 004733C



(Akshay Jain)
Partner
M. No.447487
UDIN: 26447487UOCHBH2111

Date: 09/02/2026
Place: Indore